3rd Novel IVD Congress China 2017

In the medical industry, IVD is an important segment which has a broad market and a rapid development. Affected by the impact of medical insurance fees, the addition of domestic medical institutions drug is gradually canceled, diagnosis and other medical projects usher in a new space for development. In this context, IVD industry is expected to benefit from the trend of health care reform, to maintain a rapid growth rate. Mass spectrometry, advanced sequencing technology, PCR, gene chips and other cutting-edge IVD technology is promising.
 
Although compared with foreign mature markets, the domestic IVD market shows the characteristics of a small base and a rapid growth, but the enterprises generally has small scale and less variety. The forefront of the development of IVD technology in the country is still faced with a higher threshold, how to break through the bottleneck of technology, expand the clinical application of space and other challenges are always severe. At the same time, how to realize the effective integration and docking of the clinical and independent laboratories is more important. IVD industry's latest policy trends and investment direction and other issues are also highly focused.
 
Therefore, facing the above challenges, the 3rd Novel IVD Congress China will provide you with the popular IVD industry policy and development strategy, the development of medical laboratory, the exploration of the frontier IVD technique and clinical application, so as to build a broad communication platform for stakeholders.

The 21st century is the century of life science.

The Bio-energy Park and Bio-manufacturing Park will have total area of 5 square kilometers, Wuhan National Bio-industry Base (i.e. Biolake), located at Wuhan East-Lake National Innovation Demonstration Area, is the second state-level industrial cluster built by Optics Valley of China, targeting “100-billion-RMB industry”.

During the past 5 years of development, Biolake adhered to the international industry standard and global R&D frontier. Six platforms, including technical support, public service, incubation, information sharing, investment & financing and talent introduction, have been built. Eight Global Fortune 500 Enterprises, 13 domestic listed companies, 258 domestic and oversea high-level teams settled down. The growth rate of major economic indicators is over 40%. Realized a “five-five” goal: 5 major parks formed; over 5 million square meters have been constructed; clustered 546 enterprises; annual total revenue exceeded 50 billion RMB; and 5 world-class innovation achievements have been industrialized. Biolake has established an international benchmark for the bio-industry of China.It is estimated that, by 2018, at the 10th anniversary, the total revenue of Biolake will reach over 200 billion RMB and become a world-class bio-industry cluster.

Biolake, your new opportunity and new start!